Life Science Connect Blog

  1. FDA News Roundup: Biogen Idec, GSK, Roche, And More 5/8/2015

    What regulatory decisions have you missed lately?

  2. Are We Seeing Innovation In The “Me Too” Hep C Space? 5/5/2015

    The whirlwind hepatitis C therapeutic market seems to have accelerated in the past few weeks. When I think about industry competition, even the high-profile non-small cell lung cancer (NSCLC) immunotherapy race and the sprint to approve the promising PCSK9 inhibitors for cholesterol pale in comparison to hepatitis C. Perhaps this interest was born out of the drama of the AbbVie/Gilead/Express Scripts pricing hoopla, but it certainly seems this market has grabbed the industry’s attention and won’t let it go.

  3. FDA News Roundup: Kythera Bio, Boehringer Ingelheim, GW Pharma, And More 5/1/2015

    What recent FDA decisions did you miss?

  4. Measuring Pharma Productivity: Should Biopharma Kick Eroom's Law To The Curb? 4/24/2015

    I’m sure you’ve heard that, in terms of new drug approvals, pharma had a productive 2014. There were 51 new treatments approved by the FDA’s Center for Drug Evaluation and Research (CDER) and the FDA’s Center for Biologics Evaluation and Research. According to PhRMA, member companies have invested more than $600 billion on drug R&D since 2000. Last year alone, biopharmaceutical R&D spending hit $51.2 billion.

  5. FDA News Roundup: AstraZeneca, Pfizer, AbbVie, Actavis, And More 4/24/2015

    What FDA decisions did you miss this week?

  6. Leadership Lessons From 23andMe's Jump Into Drug Discovery 4/17/2015

    23andMe has been the center of attention quite a bit recently — not only because of its high profile partnerships with Pfizer and Genentech, but also because of the recent FDA approval of its carrier test for Bloom Syndrome. However, perhaps the biggest news for the company as of late was the announcement it is jumping into the drug discovery space.

  7. FDA News Roundup: Teva, AstraZeneca, Amgen, Medicines Company, And More 4/17/2015

    What FDA decisions did you miss this week?

  8. Will China Ever See Its Own Blockbuster Drug? 4/10/2015

    It’s no secret that China is trying to become an attractive destination for companies looking to hold clinical trials and develop and manufacture drugs overseas. However, I’m also curious about what we can and should expect from the country in terms of innovation — especially when it comes to developing its own high profile drug.

  9. FDA News Roundup: Novo Nordisk, AstraZeneca, Merck, And More 4/10/2015

    What FDA decisions did you miss this week?

  10. Where Did The Biobetters Buzz Go? 4/2/2015

    The past few weeks, it seems the word on everyone’s tongue — including my own — has been biosimilars. Since the approval of Novartis’ Zarzio in the U.S., there’s been a lot of discussion and speculation about how this important approval will affect current blockbusters on the market and who will enter the space next. But I’m left with another question: What happened to the buzz over biobetters?